Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Areas with lower population density have not seen the same slowdown as urban areas.
If passed, the law would boost liver disease research and create a national strategy to tackle non-alcoholic steatohepatitis.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
This connection may be attributable to lower iron levels.
Women have a lower risk of heart disease than men, but this protective effect is diminished in those with fatty liver disease.
Those with fatty liver disease and cirrhosis should undergo regular screening.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
This finding may help explain why people with the disease struggle to lose weight.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
But experts advise caution, as the drug may worsen other liver diseases, including viral hepatitis.
A healthy diet is an essential ingredient for liver health, especially for those with fatty liver disease.
NAFLD appears to have a “bidirectional” course in patients with type 2 diabetes, according to new findings.
Madrigal Pharmaceuticals is the latest company to enter into what’s becoming a crowded market.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.